Comparison of gefitinib, erlotinib and afatinib in non‐small cell lung cancer: A meta‐analysis-Reference-Cited by-同舟云学术

Comparison of gefitinib, erlotinib and afatinib in non‐small cell lung cancer: A meta‐analysis

Published:2017-03-27 Issue:12 Volume:140 Page:2805-2819
ISSN:0020-7136
Container-title:International Journal of Cancer
language:en
Short-container-title:Int. J. Cancer

Author:

Yang Zuyao¹²^ORCID,Hackshaw Allan³,Feng Qi¹,Fu Xiaohong¹,Zhang Yuelun¹,Mao Chen¹⁴,Tang Jinling¹²⁴

Affiliation:

1. Division of Epidemiologythe Jockey Club School of Public Health and Primary Care, the Chinese University of Hong KongHong Kong China

2. The Hong Kong Branch of the Chinese Cochrane Centre, the Chinese University of Hong KongHong Kong China

3. Cancer Research UK and University College London Cancer Trials Centre90 Tottenham Court RdLondonW1T 4TJ United Kingdom

4. Shenzhen Key Laboratory for Health Risk AnalysisShenzhen Research Institute of the Chinese University of Hong KongShenzhen Guangdong Province China

Funder

Faculty Postdoctoral Fellowship Scheme from Faculty of Medicine of the Chinese University of Hong Kong

Publisher

Wiley

Subject

Cancer Research,Oncology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/ijc.30691

Reference124 articles.

1. Treatment of Non–Small-Cell Lung Cancer with Erlotinib or Gefitinib

2. Impact of EGFR Inhibitor in Non–Small Cell Lung Cancer on Progression-Free and Overall Survival: A Meta-Analysis

3. Erlotinib in Previously Treated Non–Small-Cell Lung Cancer

4. Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer)

5. Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors vs Conventional Chemotherapy in Non–Small Cell Lung Cancer Harboring Wild-Type Epidermal Growth Factor Receptor

Cited by 168 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Anti-HDGF Antibody Targets EGFR Tyrosine Kinase Inhibitor–Tolerant Cells in NSCLC Patient-Derived Xenografts;Cancer Research Communications;2024-09-01

2. Integrated single-cell and bulk RNA sequencing analyses reveal the impact of tryptophan metabolism on prognosis and immunotherapy in colon cancer;2024-08-11

3. Revolutionizing non‐melanoma skin cancer treatment: Receptor tyrosine kinase inhibitors take the stage;Journal of Cosmetic Dermatology;2024-05-29

4. Design and synthesis of N-aryl-2-trifluoromethyl-quinazoline-4-amine derivatives as potential Werner-dependent antiproliferative agents;Molecular Diversity;2024-05-13

5. Review of Personalized Medicine and Pharmacogenomics of Anti-Cancer Compounds and Natural Products;Genes;2024-04-08